For the year ending 2025-12-31, LYEL had -$45,521K decrease in cash & cash equivalents over the period. -$150,804K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -274,448 |
| Acquired ipr&d expense | 66,332 |
| Stock-based compensation expense | 41,829 |
| Loss on securities purchase agreement put/call | -19,185 |
| Depreciation and amortization expense | 11,539 |
| Net amortization and accretion on marketable securities | 4,959 |
| Non-cash lease income | 3,550 |
| Loss on property and equipment disposals, net | -3,344 |
| Change in fair value of contingent consideration payable | 1,706 |
| Impairment of long-lived assets | 1,443 |
| Change in fair value of success payment liabilities | 831 |
| Impairment of other investments | 0 |
| Loss (gain) on marketable equity security | -30 |
| Prepaid expenses, other current assets and other assets | -2,823 |
| Accounts payable | -2,339 |
| Accrued liabilities and other current liabilities | -7,642 |
| Other non-current liabilities | -2,736 |
| Net cash used in operating activities | -150,024 |
| Purchases of property and equipment | 780 |
| Sales of property and equipment | 287 |
| Purchases of marketable securities | 278,899 |
| Maturities of marketable securities | 374,684 |
| Acquisition of assets, net of cash acquired | 41,195 |
| Net cash provided by investing activities | 54,097 |
| Proceeds from securities purchase agreement equity issuance | 50,000 |
| Proceeds from exercise of stock options | 42 |
| Proceeds from employee stock purchase plan | 365 |
| Taxes paid related to net share settlement of equity awards | 1 |
| Net cash provided by financing activities | 50,406 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -45,521 |
| Cash, cash equivalents and restricted cash at beginning of period | 107,287 |
| Cash, cash equivalents and restricted cash at end of period | 61,766 |
Lyell Immunopharma, Inc. (LYEL)
Lyell Immunopharma, Inc. (LYEL)